STUDY: In Vitro and In Vivo Antimicrobial Activity of the Novel Peptide OMN6 against Multidrug-Resistant Acinetobacter baumannii

The rapid worldwide spread of antimicrobial resistance (AMR) underscores the significant need for the development of innovative treatments to fight multidrug-resistant bacteria. Our Scientists at Omnix Medical have published a study demonstrating the potent antimicrobial activity of the novel peptide OMN6 against a wide array of drug-resistant Acinetobacter baumannii. Results point to OMN6 as a novel antimicrobial agent targeting the most troubling bacteria with a novel mechanism of action, positioning our technology as the potential SoC to treat life-threatening infections caused by MDR bacteria. READ STUDY PUBLISHED 5 September 2022. In Vitro and In Vivo Antimicrobial Activity of the Novel Peptide OMN6 against Multidrug-Resistant Acinetobacter baumannii Download

The release as fetched from its publisher. omnixmedical.com ↗